Motivation. Cephalosporins are a class of beta-lactam antibiotics widely used in clinics for their antibacterial activity. Their mode of action, common to other beta lactam antibiotics such as penicillins, is the impairment of the synthesis of the peptidoglycan forming the bacterial cell wall. This polymer, essential for bacterium survival, is made by aminosugars connected by glycosidic bonds to form linear chains, and by short peptides forming cross-links between the linear chains. The enzymes catalyzing the creation of these cross-links are transpeptidases, also called penicillin binding proteins (PBPs) for their ability to interact with penicillins and other beta lactam antibiotics. These molecules mimic the D-Ala-DAla terminus of the peptides, therefore they competitively inactivate the PBPs by binding covalently to the Ser residue responsible for the catalysis and stopping the transpeptidation. This results in cell lysis and bacterial death. One of the main problems to face when using cephalosporins is the development of several mechanisms of resistance, either for the reduced affinity of PBPs to the beta lactams, or for the selection of new beta-lactam-insensitive PBPs, or for the production of beta lactamases, enzymes able to hydrolyze the beta lactam ring, thus deactivating the antibiotics. Additionally, most cephalosporins have a limited spectrum of action, against only Gram+ or Gram-bacteria. Therefore, during the time, many new beta lactam antibiotics have been synthesized with the aim of broadening the spectrum of action and/or overcoming the resistance. The prototype of a new group of cephalosporins is AMA-10, in which another beta lactam ring bound to a short alkyl chain has been linked to the aminocephalosporanic ring by means of an amidic bond. In order to develop other molecules, however, it is essential to understand how they interact with their target. Therefore, to apply a rational approach for the design of new derivatives, we have performed a computational study by simulating the binding of AMA-10 to selected PBPs of different species, whose crystallographic structures were available, using a particular approach, covalent docking, able to take into account the covalent bond formed between the antibiotic and the enzyme.
